The future trajectory of Aquestive Therapeutics (AQST) stock is heavily dependent on regulatory decisions by health authorities, commercial adoption rates for its proprietary drug delivery platforms, and ongoing clinical trial success. Equity analysts track its path toward profitability as it works to secure approvals and expand commercial partnerships for specialty pharmaceutical products. Because small-cap specialty pharma equities are susceptible to high volatility based on regulatory milestones, future performance remains closely tied to corporate execution.